5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Acute Lymphoblastic Leukemia Therapeutics Market is segmented by Type of Cell, Type of Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation), and Geography
Fastest Growing Market:
One of the major factors responsible for the growth of this market includes the rising occurrence of acute lymphoblastic leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.
There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.
As per the scope of the report, acute lymphoblastic leukemia (ALL), also called lymphoblastic leukemia, is one of the most common types of cancer, which spreads in the body through lymph nodes, spinal cord, liver, spleen, and central nervous system, among others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL. B-cell ALL is the most common type. The treatment of patients with Ph+ ALL involves precise drugs that target the gene products.
|By Type of Cell|
|Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL|
|By Type of Therapy|
|Stem Cell Transplantation|
Report scope can be customized per your requirements. Click here.
The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.
Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. ALL is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to high prevalence of ALL, especially among children.
To understand key trends, Download Sample Report
North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.
Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.
To understand geography trends, Download Sample Report.
The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
4.2.2 Increasing Initiatives Taken by the Government and Private Organizations
4.3 Market Restraints
4.3.1 Stringent Regulatory Pathways
4.3.2 High Cost Asscoiated with the Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Cell
5.1.1 B-cell ALL
5.1.2 T-cell ALL
5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
5.2 By Type of Therapy
188.8.131.52 Hyper - CVAD Regimen
184.108.40.206 CALGB 8811 Regimen
220.127.116.11 Linker Regimen
18.104.22.168 Nucleoside Inhibitors
22.214.171.124 Other Types of Therapies
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.4 Stem Cell Transplantation
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
5.3.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol Myer Squibb Company
6.1.2 Celegene Corporation
6.1.3 Eisai Co Ltd
6.1.4 Erytech Pharma
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genmab A/S
6.1.7 GlaxoSmithKline PLC
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Sanofi SA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments